# Novo Nordisk

Type: Company (NVO)

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/novo-nordisk-company
Canonical HTML page: https://getlegalbrief.com/entity/novo-nordisk-company

## Timeline

- **2026-07-21**: Lawsuit Filed — Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.
- **2026-07-21**: Lawsuit filed — Novo Nordisk sues Eli Lilly in federal court, alleging misleading advertising.
- **2026-04**: Cease-and-desist letter — Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads.
- **2026-03-09**: Settlement & Collaboration — Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.
- **2026-03**: Settlement Reached — Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
- **2026-03**: FDA Approves Wegovy 7.2 mg — Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.
- **2026-03**: High-dose Wegovy approved — Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound.
- **2025-10-15**: Supply Stabilization — FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.
- **2025**: Litigation Surge — Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
- **2024**: FDA Shortage Updates — FDA begins removing specific GLP-1 dosages from the national shortage list.
- **2024-05-20**: Hims & Hers GLP-1 Launch — Hims & Hers announces the launch of compounded GLP-1 injections at a significant discount to brand names.
- **2024-05**: HIMS Launches GLP-1s — Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
- **2023-06-01**: Litigation Wave Begins — Novo Nordisk starts filing lawsuits against medical spas and pharmacies over compounded semaglutide.

## Recent coverage (4 stories)

### Novo Nordisk sues Eli Lilly under Lanham Act over 2-year-old GLP-1 ad claims
2026-07-21 22:05:06 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-misleading-glp1-ads-lanham-act

### Novo Sues Lilly: Omits Wegovy’s 19% Weight Loss, Seeks Injunction
2026-07-21 14:14:08 · Sentiment: Neutral · Impact: 7/10 · Sources: 3

Novo Nordisk alleges Lanham Act violations; case tests whether outdated comparisons in DTC ads constitute false advertising, with potential precedent for pharma.
Full story: https://getlegalbrief.com/story/novo-sues-lilly-false-advertising-glp1-injunction

### Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement
2026-03-09 17:30:26 · Sentiment: Negative · Impact: 6/10 · Sources: 2

Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Full story: https://getlegalbrief.com/story/hims-hers-glp1-settlement-regulation

### Hims & Hers and Novo Nordisk Settle GLP-1 Litigation, Pivot to Collaboration
2026-03-09 17:29:52 · Sentiment: Positive · Impact: 6/10 · Sources: 5

Hims & Hers Health and Novo Nordisk have reached a settlement to end their legal dispute over compounded weight loss medications. The agreement transitions the relationship from adversarial litigation to a strategic collaboration, potentially reshaping the telehealth distribution model for GLP-1 drugs.
Full story: https://getlegalbrief.com/story/hims-hers-novo-nordisk-glp1-settlement-collaboration

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.